<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487277</url>
  </required_header>
  <id_info>
    <org_study_id>144515</org_study_id>
    <secondary_id>NCI-2015-01213</secondary_id>
    <nct_id>NCT02487277</nct_id>
  </id_info>
  <brief_title>PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma</brief_title>
  <official_title>Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Ko</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will be conducting a Phase II study investigating PEGPH20 in combination with gemcitabine
      and nab-paclitaxel in patients with borderline resectable pancreatic ductal adenocarcinoma
      (PDAC) at the Helen Diller Family Comprehensive Cancer Center at University of California,
      San Francisco (UCSF). There are multiple definitions of borderline resectable PDAC including
      the MD Anderson definition and the criteria developed during the Consensus Conference
      sponsored by the American Hepato-Pancreato-Biliary Association, Society of Surgical Oncology,
      and Society for Surgery of the Alimentary Tract. Borderline resectable PDAC cases will be
      identified per the definition developed in the currently running inter-group pilot trial for
      borderline resectable pancreatic cancer (NCT01821612). Per this trial, borderline resectable
      PDAC is defined as &quot;presence of any one or more of the following on CT:

        -  An interface between the primary tumor and the superior mesenteric vein or portal vein
           (SMV-PV) measuring ≥ 180° of the circumference of the vessel wall

        -  Short-segment occlusion of the SMV-PV with normal vein above and below the level of
           obstruction that is amenable to resection and venous reconstruction

        -  Short segment interface (of any degree) between tumor and hepatic artery with normal
           artery proximal and distal to the interface that is amenable to resection and
           reconstruction.

        -  An interface between the tumor, and Superior mesenteric artery (SMA) measuring &lt; 180º of
           the circumference of the vessel wall.

      This trial will be conducted in two parts. In Part I, pre-treatment endoscopic ultrasound
      (EUS)-guided core biopsies of the pancreatic tumor, CA 19-9 levels and functional MRIs
      including Dynamic contrast-enhanced (DCE)-MRI and Diffusion-weighted magnetic resonance
      imaging (DWI-MRI) will be obtained for the first fifteen patients enrolled. After a 1-week
      run-in period with PEGPH20 on days 1 and 4, patients will have repeat EUS-guided core
      biopsies, functional MRI, CA 19-9 level and baseline CT chest, abdomen and pelvis.
      Subsequently, patients will be started on treatment with PEGPH20, gemcitabine and
      nab-paclitaxel given weekly for 3 weeks, every 28 days. To evaluate the disease response to
      treatment, CA 19-9 levels will be checked monthly and restaging CT chest, abdomen and pelvis
      will be obtained every 8 weeks. If there is disease progression at any point in the study,
      patients will be taken off of study and alternative treatments will be offered. At the
      completion of 4 cycles of therapy, restaging CT scans will be obtained to determine
      resectability. If the patients are found to have resectable disease, an additional functional
      MRI will be obtained to evaluate the PDAC stroma. If the patients are able to have successful
      surgeries, tissue analyses will be performed on the resected pancreatic tumor. These patients
      will then proceed to get 2 cycles of adjuvant chemotherapy with gemcitabine and
      nab-paclitaxel. If the patients are deemed to be surgical candidates but are found to have
      unresectable disease in the operating room, an intraoperative core biopsy of the pancreatic
      tumor will be obtained for tissue analyses. At the time of initiation of therapy with
      PEGPH20, patients will be started on prophylactic dose of enoxaparin 1 mg/kg subcutaneous
      daily. This will be continued throughout the study participation.

      In Part II, an additional 21 patients will be enrolled, and will begin neoadjuvant therapy
      with PEGPH20, gemcitabine and nab-paclitaxel without the 1 week run-in of PEGPH20-only or the
      pre- and post-run-in EUS-guided biopsies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For Specific Aim 1, we will be monitoring the post-operative complication of clinically
      relevant pancreatic fistula within one week of surgery per the standard clinical guidelines
      as noted above. Common clinical presentations of pancreatic fistula include abdominal pain,
      leukocytosis and fever (temperature &gt;100.4 degrees). Diagnostic work-up of pancreatic fistula
      will be with CT abdomen with contrast, which has a sensitivity of 63% and specificity of 83%
      for detecting pancreatic fistula. The pancreatic fistulas will be categorized into grades A,
      B or C as previously reported. Our study will be investigating only clinically relevant
      pancreatic fistulas, i.e. grades B or C. Depending on the grade of pancreatic fistula,
      patients will be treated as indicated with conservative treatment options including bowel
      rest, antibiotics, somatostatin analogues and percutaneous drainage or surgical
      re-exploration. We will also track other relevant post-operative complications such as
      delayed wound healing, development of wound dehiscence or wound infection.

      The tissue analyses will include review of the immunohistochemical (IHC) stains for actin,
      hyaluronic acid staining with binding protein probe, proliferation as measured by ki-67% and
      Phospho-histone H3 (Ph-H3); cell apoptosis as evaluated by IHC stain for cleaved caspase 3
      (CC3) and Tunel. If limited tissue sample is obtained via the core biopsies, the priority of
      tissue analysis will be as follows: (1) fixed in formalin for H&amp;E and IHC (Ph-H3; CC3/Tunel;
      Hyaluronic Acid (HA) binding); (2) fixed in Optimal Cutting Temperature (OTC) such that IHC
      with difficult antibodies can be done (to potentially obtain mRNA or DNA). The IHC studies
      will be done at the UCSF Helen Diller Family Comprehensive Cancer Center Immunohistochemistry
      and Molecular Pathology Core. The tissue analyses of the biopsy and surgical specimens will
      be done by study pathologist.

      The CT and magnetic resonance (MR) imaging analyses will be performed at the Abdominal
      Imaging at UCSF. To decrease the impact that metal stents may have on the functional MRI
      results, we will include only patients who have plastic stents in our study. In addition, to
      reduce variability in results, the DCE-MRI and DWI-MRI will be obtained on the same MR
      machine at a similar time of day as the baseline scan. The DCE-MRI images will be analyzed by
      calculating Ktrans and DWI-MRI images will be analyzed by calculating apparent diffusion
      coefficient (ADC) as described elsewhere. We will scan patients in a torso coil on a 3T
      clinical MR scanner. Imaging will include MR diffusion with b-values of 0, 125, and 500 for
      estimates of perfusion and tumor, and dynamic contrast-enhanced MR imaging (DCE-MRI) for
      measurement of Ktrans, blood volume, and blood flow. The region of tumor will be determined
      by MR imaging in reference to the baseline CT scans. The native T1 of the pancreas and liver
      will be calculated from a series of four, 3D, spoiled gradient recalled echo (SPGR) sequences
      with different flip angles. The conventional DCE-MRI will be acquired as a 3D, fast spoiled
      gradient echo sequence, covering the targeted areas of the pancreas or liver, at a temporal
      resolution of 5 sec over 6 minutes after the administration of 0.1 mmol/kg gadobenate
      dimeglumine. DCE-MRI images will be post-processed using MIStar software (Apollo Medical
      Imaging, Melbourne, Australia), which allows for motion correction to account for any shifts
      in data. Datasets with artifacts will be eliminated before further post processing. After
      contrast delivery, the new T1 is calculated and is presumed to change with the Gd
      concentration such that [Gd] = (1/T1-1/T10)/R1 where R1 is assumed to be 4.5 sec-1 mmol/L-1
      at 3T.

      Run-in Period with PEGPH20

      - Days 1, 4

      PEGPH20 3 ug/kg Dexamethasone 8mg PO 1-2 hours pre-PEGPH20 and PO 8-to-12 hours post-PEGPH20

      *Start enoxaparin 1 mg/kg subcutaneous daily on day 1 (to be continued throughout the trial)

      - On day 8 of run-in period with PEGPH20, EUS-directed core biopsy, CA 19-9, functional MRI
      and CT chest, abdomen (pancreatic protocol) and pelvis will be obtained.

      Cycle 1 and onward

      -Day 1, 8, 15

      PEGPH20 3 ug/kg + Gemcitabine 1000mg/m2 + nab-Paclitaxel 125mg/m2 Dexamethasone 8mg PO 1-2
      hours pre-PEGPH20 and PO 8-to-12 hours post-PEGPH20

        -  Gemcitabine and nab-paclitaxel will be administered 2-4 hours post-PEGPH20.

        -  Neoadjuvant therapy will be four 28-day cycles with CT chest, abdomen and pelvis scans
           and CA 19-9 measurements every 8 weeks. Patients will be taken off of the study if there
           is any evidence of disease progression.

        -  After four cycles of neoadjuvant therapy, patients will be evaluated for surgical
           resection depending on the CT scan findings obtained on cycle 4, day 21.

        -  If they have resectable disease, they will have a functional MRI following the restaging
           CT scan. If patients have successful resection, they will receive 2 additional cycles of
           gemcitabine and nab-paclitaxel. If they are found to have unresectable disease in the
           operating room, an intra-operative core biopsy will be obtained.

        -  If they have unresectable disease on the restaging scans following 4 cycles of therapy,
           they will be taken off of the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual
  </why_stopped>
  <start_date type="Actual">July 14, 2015</start_date>
  <completion_date type="Actual">May 18, 2018</completion_date>
  <primary_completion_date type="Actual">May 18, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Clinically Relevant Pancreatic Fistula</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Our study will be investigating only clinically relevant pancreatic fistulas, i.e. grades B or C. Descriptive statistics will be used report the incidence of pancreatic fistula within the 7-day post-operative period after neoadjuvant treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Pathologic Complete Response (pCR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Descriptive statistics with frequency / proportion will be used to evaluate rate of pathologic complete response using the pathological exam of resected tumors. pCR was defined as area of scarring in pancreatic parenchyma and/or peripancreatic soft tissue with chronic inflammation, with or without acellular mucin pools and histiocytic infiltrates, but no residual viable invasive adenocarcinoma cells in the pancreatectomy specimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change of CA19-9 Response Rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>To evaluate the disease response to treatment, CA19-9 levels will be measured every 4 weeks and restaging Computerized tomography (CT) / magnetic resonance imaging (MRI)of the chest, abdomen and pelvis will be obtained every 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Margin-Negative (R0) Resection Rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Patients will be evaluated for surgical resection depending on imaging obtained on Cycle 4 Day 21. R0 Resection rate determined by CA 19-9 levels will be checked every 4 weeks and restaging CT/MRI of the chest, abdomen and pelvis will be obtained every 8 weeks surgical resection if the patient's tumor is deemed resectable post-therapy. Patients who have received at least 2 complete, 28-day cycles of study drugs were included in the secondary analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Descriptive statistics with frequency and proportion of overall response determined by CA 19-9 levels will be checked every 4 weeks and restaging CT/MRI of the chest, abdomen and pelvis will be obtained every 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier methods will be used to analyze disease free survival and median time and 95% confidence intervals will be reported</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Combination therapy with 1 week Run-In</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEGPH20: 3ug/kg on Days 1 and 4
1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEGPH20</intervention_name>
    <arm_group_label>Combination therapy alone</arm_group_label>
    <arm_group_label>Combination therapy with 1 week Run-In</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Combination therapy alone</arm_group_label>
    <arm_group_label>Combination therapy with 1 week Run-In</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <arm_group_label>Combination therapy alone</arm_group_label>
    <arm_group_label>Combination therapy with 1 week Run-In</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than or equal to 18 years old

          -  Histologically confirmed pancreatic adenocarcinoma

          -  Borderline resectable disease

          -  Performance status of Eastern Cooperative Oncology Group (ECOG) of 0-1

          -  Therapy naïve

          -  Evaluable disease with either:

          -  RECIST-defined measurable disease

          -  An elevated serum CA19-9 &gt;100 u/ml

          -  Adequate organ function including:

          -  Bone marrow: Absolute Neutrophil Count (ANC) ≥1500/mm3, platelets ≥100,000/mm3 and
             hemoglobin ≥ 9 g/dL

          -  Hepatic: Serum total bilirubin ≤1.5 x upper limit of normal (ULN), alanine
             aminotransferase (ALT)/ serum glutamic-pyruvic transaminase (SGPT) and aspartate
             aminotransferase (AST)/ serum glutamic-oxaloacetic transaminase (SGOT) ≤ 2.5 x ULN.

          -  Renal: Serum creatinine (sCr) ≤ 1.5 x ULN, or creatinine clearance (Ccr) ≥ 40 mL/min
             as calculated by the Modified Cockcroft-Gault formula.

          -  Peripheral neuropathy &lt; grade 2

          -  Alkaline phosphatase ≤ 2 times the ULN unless bone metastasis is present in the
             absence of liver metastasis

        Exclusion Criteria:

          -  Age younger than 18 years old

          -  Locally advanced or metastatic disease

          -  Known allergy to hyaluronidase

          -  Contraindications to prophylactic dose low molecular weight heparin (LMWH) , including

          -  Patients with recent gastrointestinal bleeding

          -  History of heparin induce thrombocytopenia on LMWH

          -  Subjects with previous severe hemorrhagic events on LMWH

          -  Known contraindications to heparin including:

          -  Recent central nervous system bleed, intracranial or spinal lesion at high risk for
             bleeding

          -  Active bleeding (major): more than 2 units transfused in 24 hours

          -  Spinal anesthesia/lumbar puncture within the past month

          -  Chronic, clinically significant measurable bleeding &gt; 48 hours

          -  Severe platelet dysfunction (uremia, medications, dysplastic hematopoiesis)

          -  Recent major operation at high risk for bleeding

          -  Underlying hemorrhagic coagulopathy High risk for falls (head trauma)

          -  Presence of metal biliary stents (plastic biliary stents are not an exclusion)

          -  Known status of HIV which is not well-controlled at the time of study eligibility

          -  Untreated Hepatitis B infection

          -  Active infection or antibiotics within 48 hours prior to study

          -  Currently active second primary malignancy or history of malignancy less than 5 years
             prior to the time of study eligibility (Patients with history of skin cancers
             excluding melanoma will be eligible for participation).

          -  Serious medical comorbidities such as New York Heart Association Class III/IV cardiac
             disease, uncontrolled cardiac arrhythmias, myocardial infarction over the past 12
             months.

          -  Patients with aneurysm clips, ear implants, spinal nerve stimulators, pacemaker,
             shrapnel or any other metal in their body (contraindication for MRI scans)

          -  Known, existing uncontrolled coagulopathy. Patients who have had a venous
             thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring
             anticoagulation are eligible IF: they are appropriately anticoagulated and have not
             had a Grade 2 or greater bleeding episode in the 3 weeks before Day 1.

          -  Current use of warfarin (patients will be eligible if warfarin is discontinued and
             low-molecular weight heparin is used instead).

          -  Intolerance to dexamethasone

          -  Prior history of cerebrovascular accident or transient ischemic attack, or
             pre-existing carotid artery disease.

          -  Known pregnancy, nursing women or positive pregnancy test.

          -  Any condition that would preclude informed consent, consistent follow-up and
             compliance for the study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Ko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <results_first_submitted>December 4, 2019</results_first_submitted>
  <results_first_submitted_qc>December 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2020</results_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Andrew Ko</investigator_full_name>
    <investigator_title>Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>Pancreatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02487277/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02487277/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study was terminated earlier than expected due to low accrual so no participants were enrolled in the &quot;Combination therapy alone&quot; treatment arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combination Therapy With 1 Week Run-In</title>
          <description>PEGPH20: 3ug/kg on Days 1 and 4
1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20
Gemcitabine
Nab-paclitaxel</description>
        </group>
        <group group_id="P2">
          <title>Combination Therapy Alone</title>
          <description>1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20
Gemcitabine
Nab-paclitaxel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study was terminated prior to enrollment in arm without run-in period (Combination therapy alone)</population>
      <group_list>
        <group group_id="B1">
          <title>Combination Therapy With 1 Week Run-In</title>
          <description>PEGPH20: 3ug/kg on Days 1 and 4
1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20
Gemcitabine
Nab-paclitaxel</description>
        </group>
        <group group_id="B2">
          <title>Combination Therapy Alone</title>
          <description>1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20
Gemcitabine
Nab-paclitaxel</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>50-59 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Clinically Relevant Pancreatic Fistula</title>
        <description>Our study will be investigating only clinically relevant pancreatic fistulas, i.e. grades B or C. Descriptive statistics will be used report the incidence of pancreatic fistula within the 7-day post-operative period after neoadjuvant treatment</description>
        <time_frame>Up to 5 years</time_frame>
        <population>No data was collected for these patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy With 1 Week Run-In</title>
            <description>PEGPH20: 3ug/kg on Days 1 and 4
1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20
Gemcitabine
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Combination Therapy Alone</title>
            <description>1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Clinically Relevant Pancreatic Fistula</title>
          <description>Our study will be investigating only clinically relevant pancreatic fistulas, i.e. grades B or C. Descriptive statistics will be used report the incidence of pancreatic fistula within the 7-day post-operative period after neoadjuvant treatment</description>
          <population>No data was collected for these patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Pathologic Complete Response (pCR)</title>
        <description>Descriptive statistics with frequency / proportion will be used to evaluate rate of pathologic complete response using the pathological exam of resected tumors. pCR was defined as area of scarring in pancreatic parenchyma and/or peripancreatic soft tissue with chronic inflammation, with or without acellular mucin pools and histiocytic infiltrates, but no residual viable invasive adenocarcinoma cells in the pancreatectomy specimen</description>
        <time_frame>Up to 5 years</time_frame>
        <population>No data was collected for these patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy With 1 Week Run-In</title>
            <description>PEGPH20: 3ug/kg on Days 1 and 4
1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20
Gemcitabine
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Combination Therapy Alone</title>
            <description>1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Pathologic Complete Response (pCR)</title>
          <description>Descriptive statistics with frequency / proportion will be used to evaluate rate of pathologic complete response using the pathological exam of resected tumors. pCR was defined as area of scarring in pancreatic parenchyma and/or peripancreatic soft tissue with chronic inflammation, with or without acellular mucin pools and histiocytic infiltrates, but no residual viable invasive adenocarcinoma cells in the pancreatectomy specimen</description>
          <population>No data was collected for these patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of CA19-9 Response Rate</title>
        <description>To evaluate the disease response to treatment, CA19-9 levels will be measured every 4 weeks and restaging Computerized tomography (CT) / magnetic resonance imaging (MRI)of the chest, abdomen and pelvis will be obtained every 8 weeks</description>
        <time_frame>Up to 5 years</time_frame>
        <population>No data was collected for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy With 1 Week Run-In</title>
            <description>PEGPH20: 3ug/kg on Days 1 and 4
1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20
Gemcitabine
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Combination Therapy Alone</title>
            <description>1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of CA19-9 Response Rate</title>
          <description>To evaluate the disease response to treatment, CA19-9 levels will be measured every 4 weeks and restaging Computerized tomography (CT) / magnetic resonance imaging (MRI)of the chest, abdomen and pelvis will be obtained every 8 weeks</description>
          <population>No data was collected for this endpoint</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Margin-Negative (R0) Resection Rate</title>
        <description>Patients will be evaluated for surgical resection depending on imaging obtained on Cycle 4 Day 21. R0 Resection rate determined by CA 19-9 levels will be checked every 4 weeks and restaging CT/MRI of the chest, abdomen and pelvis will be obtained every 8 weeks surgical resection if the patient's tumor is deemed resectable post-therapy. Patients who have received at least 2 complete, 28-day cycles of study drugs were included in the secondary analyses</description>
        <time_frame>Up to 5 years</time_frame>
        <population>No data was collected for these patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy With 1 Week Run-In</title>
            <description>PEGPH20: 3ug/kg on Days 1 and 4
1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20
Gemcitabine
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Combination Therapy Alone</title>
            <description>1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20</description>
          </group>
        </group_list>
        <measure>
          <title>Margin-Negative (R0) Resection Rate</title>
          <description>Patients will be evaluated for surgical resection depending on imaging obtained on Cycle 4 Day 21. R0 Resection rate determined by CA 19-9 levels will be checked every 4 weeks and restaging CT/MRI of the chest, abdomen and pelvis will be obtained every 8 weeks surgical resection if the patient's tumor is deemed resectable post-therapy. Patients who have received at least 2 complete, 28-day cycles of study drugs were included in the secondary analyses</description>
          <population>No data was collected for these patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>Descriptive statistics with frequency and proportion of overall response determined by CA 19-9 levels will be checked every 4 weeks and restaging CT/MRI of the chest, abdomen and pelvis will be obtained every 8 weeks</description>
        <time_frame>Up to 5 years</time_frame>
        <population>No data was collected for these patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy With 1 Week Run-In</title>
            <description>PEGPH20: 3ug/kg on Days 1 and 4
1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20
Gemcitabine
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Combination Therapy Alone</title>
            <description>1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>Descriptive statistics with frequency and proportion of overall response determined by CA 19-9 levels will be checked every 4 weeks and restaging CT/MRI of the chest, abdomen and pelvis will be obtained every 8 weeks</description>
          <population>No data was collected for these patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival (DFS)</title>
        <description>Kaplan-Meier methods will be used to analyze disease free survival and median time and 95% confidence intervals will be reported</description>
        <time_frame>Up to 5 years</time_frame>
        <population>No data was collected for these patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy With 1 Week Run-In</title>
            <description>PEGPH20: 3ug/kg on Days 1 and 4
1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20
Gemcitabine
Nab-paclitaxel</description>
          </group>
          <group group_id="O2">
            <title>Combination Therapy Alone</title>
            <description>1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS)</title>
          <description>Kaplan-Meier methods will be used to analyze disease free survival and median time and 95% confidence intervals will be reported</description>
          <population>No data was collected for these patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Investigator and the study team will record any occurrences of Adverse Events (AEs) from the signing of the informed consent to 28 days after the last dose of study drug, or longer if the PI deems the event is related to the drug - up to 5 years</time_frame>
      <desc>All eligible patients who are enrolled into the study and receive at least one complete, 28-day cycle of the study drugs will be included in the safety analysis. Enrollment was terminated early due to low accrual, with no patients enrolled in the combination therapy alone arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combination Therapy With 1 Week Run-In</title>
          <description>PEGPH20: 3ug/kg on Days 1 and 4
1 cycle = 28 days
PEGPH20: 3ug/kg on Days 1, 8, 15
Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15
PEGPH20
Gemcitabine
Nab-paclitaxel</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v.4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Papulopustular rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated earlier than expected due to low accrual so no participants were enrolled in the &quot;Combination therapy alone&quot; treatment arm.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Andrew Ko</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 353-7286</phone>
      <email>Andrew.Ko@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

